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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes death within a mean of 2–3 years from
symptom onset. There is no diagnostic test and the delay from symptom onset to diagnosis averages 12 months. The
identification of prognostic and diagnostic biomarkers in ALS would facilitate earlier diagnosis and faster monitoring of
treatments. Gene expression profiling (GEP) can help to identify these markers as well as therapeutic targets in neurological
diseases. One source of genetic material for GEP in ALS is peripheral blood, which is routinely accessed from patients.
However, a high proportion of globin mRNA in blood can mask important genetic information. A number of methods allow
safe collection, storage and transport of blood as well as RNA stabilisation, including the PAXGENE and TEMPUS systems for
the collection of whole blood and LEUKOLOCK which enriches for the leukocyte population. Here we compared these three
systems and assess their suitability for GEP in ALS. We collected blood from 8 sporadic ALS patients and 7 controls.
PAXGENE and TEMPUS RNA extracted samples additionally underwent globin depletion using GlobinClear. RNA was
amplified and hybridised onto Affymetrix U133 Plus 2.0 arrays. Lists of genes differentially regulated in ALS patients and
controls were created for each method using the R package PUMA, and RT-PCR validation was carried out on selected
genes. TEMPUS/GlobinClear, and LEUKOLOCK produced high quality RNA with sufficient yield, and consistent array
expression profiles. PAXGENE/GlobinClear yield and quality were lower. Globin depletion for PAXGENE and TEMPUS
uncovered the presence of over 60% more transcripts than when samples were not depleted. TEMPUS/GlobinClear and
LEUKOLOCK gene lists respectively contained 3619 and 3047 genes differentially expressed between patients and controls.
Real-time PCR validation revealed similar reliability between these two methods and gene ontology analyses revealed
similar pathways differentially regulated in disease compared to controls.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal
disease that preferentially affects the motor system. Clinically, ALS
manifests as progressive weakness of voluntary muscles and
patients survive on average for 2–3 years after onset of symptoms.
The mechanisms that cause neurodegeneration in ALS are
incompletely understood, and are considered to operate through
a number of molecular and genetic pathways including glutamate
toxicity, oxidative stress, the formation of protein aggregates and
defects in axonal transport [1,2]. Therefore the identification of
biomarkers that may detect the early signs of ALS, assess disease
progression, monitor the effects of treatment, or even help identify
the cause of the disease is of great importance.
Gene expression profiling (GEP) is a powerful tool to help
identify potential diagnostic and therapeutic targets in neurological
diseases [3–5]. Analysis of global expression patterns and
differentially expressed genes in an unbiased manner allows for
identification of affected functional categories or specific pathways.
One potential source for genetic material in this type of study is
peripheral blood, which is routinely and easily accessed from
patients [3]. Although GEP of whole blood is informative in
studying the mechanisms and pathogenesis of a number of
diseases, including neurological disorders, the high proportion of
globin mRNA present in red blood cells masks potentially
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e87508
important genetic information, and increases noise, thereby
reducing sensitivity [6,7].
Conventional methods for reducing the relative amounts of
globin mRNA in blood samples by density gradient centrifugation
and extraction of the white blood cell population have been shown
to be effective in reducing globin interference. However, the long
duration of experimental handling during the extraction process
leads to RNA degradation and possible unintended gene induction
that might affect the validity of the disease related changes in gene
expression [8]. Methods that allow rapid RNA stabilization, and
long-term storage without degradation are commercially available
e.g. PAXGENE (Qiagen) and TEMPUS (Applied Biosystems) and
are currently being utilised (e.g., [6,9–11]). These methods extract
RNA from whole blood and so will be affected by globin
interference, unless an additional globin depletion step is
completed. An alternative strategy has been developed that aims
to specifically reduce the amount of globin contamination by
enriching the leukocyte population through immobilisation on a
filter (LEUKOLOCK, Ambion), thereby avoiding a globin
depletion step [12,13].
In order to discover the best method of RNA isolation from
blood to carry out GEP in a neurological disorder such as ALS, we
compared these three commercially available systems for RNA
extraction from blood. PAXGENE (PAX) and TEMPUS (TEM),
which are column based methods leading to RNA extracted from
whole blood, and LEUKOLOCK (LL), a method for isolating
white blood cells for subsequent RNA extraction. We used a
cohort of 8 sporadic ALS patients and 7, age-matched controls.
RNA from PAX and TEM extractions also underwent a step to
deplete globin using GlobinClear (GC, Ambion). Therefore, RNA
from 5 experimental conditions (TEM, TEM+GC, PAX,
PAX+GC, and LL) was hybridized onto U133 Plus 2.0 Human
whole genome arrays (Affymetrix) and analysed. A number of
genes found to be dysregulated in disease compared to controls
were confirmed by real-time PCR. This allowed us to identify
which method/condition is best suited for carrying out GEP in
ALS.
Results
RNA extraction, quality and quantity
RNA was extracted by PAX, TEM and LL as described in the
methods (Figure 1). TEM and LL both had optional DNase steps
which were omitted, and the on-column DNase step in PAX was
also not carried out to avoid potential damage to RNA quality and
yield. The quality and yield of extracted RNA was analysed by
examining electropherogram traces generated by the Agilent
Bioanlayzer running the samples on a total eukaryote RNA nano
chip, and by UV spectrography using Nanodrop. Representative
Bioanalyzer traces show that in the cases of TEM and LL, high
quality RNA (RIN .7.0) can routinely be extracted (Figure 2).
However, in the case of PAX extracted RNA, genomic DNA
contamination led to a skewing of the 28S peak, and occasionally
an additional genomic DNA peak was observed. Therefore all
PAX samples were subjected to DNase treatment. No such
contamination was observed with TEM and LL. After DNase
digestion, high quality RNA was extracted with no signs of
genomic DNA contamination, however this resulted in decreased
RNA yield. Globin mRNA depletion (GC) using the Globin Clear
kit was carried out using 1 mg of total RNA as input for each
sample.
Averages of RNA yield and RNA quality (RIN values) for each
method were quantified using the Nanodrop and Bioanalyser and
are displayed in Figures 3A and B. In terms of yield, quantity of
RNA was as follows: TEM . PAX . LL and TEM GC . PAX
GC (Figure 3A). RNA quality as measured by RIN values showed
little difference between samples, however LL tended to produce
samples with higher average RIN values, while RIN values from
PAX GC were the lowest. Although there was a reduction in RIN
values after GC in the case of PAX, the RIN values of TEM GC
samples remained high (LL, RIN=8.5, 61.0; TEM, RIN=7.9,
60.44; PAX, RIN=7.9, 60.44; TEM GC 7.9, 60.3; PAX GC
7.2, 60.59, see Figure 3B). PAX required the longest time and
most experimental manipulation to carry out, while there were
significantly less steps and time required for the other methods.
aRNA amplification and fragmentation
After the in vitro transcription (IVT) reaction all samples yielded
enough material to progress to the hybridisation step (Figure 3C),
however some PAX samples required concentrating with Glyco-
blue. Figure 4 shows representative Bioanalyzer traces from pre-
and post- fragmentation amplified RNA (aRNA). Each method
presented a distinctive aRNA profile. However, after fragmenta-
tion the profiles were not distinguishable. The profiles of LL, TEM
GC, and PAX GC exhibited IVT products over a wide range of
molecular weight sizes while PAX and TEM profiles displayed
high intensity peaks at low or medium nucleotide sizes, either
indicating degradation of product, or the high expression levels of
a particular species of RNA that disappeared upon globin mRNA
depletion. All samples were hybridised onto Human Genome
U133 Plus 2.0 arrays.
Array hybridisation and Quality Control
Quality control (QC) for the 75 hybridised arrays was carried
out. The polyA controls showed that there was no bias between
high and low expressed genes during the preparation steps
(Figure 5A). However, the different patterns of hybridisation
controls (Figure 5B) indicate that the conditions of RNA
extraction affect PAX hybridisations, causing a highly variable
profile which disappears upon globin depletion. The % present
calls (Tables 1 and 2, Figure 5C) are all consistent (,40–50%),
except for PAX (,27–39%) and TEM (,35–43%) which are
clearly lower than the others. Scale factors (Figure 5D, Table 1
and 2), were all consistent within groups, and comparing between
groups except PAX samples which were higher than the rest. Only
a few samples showed RNA degradation, and they were included
in the further analysis if the scale factor was not affected. The
relative log signal of all arrays was generally similar apart for the
outliers LL12 and TGC12 (Figure 5E), and in general signals
from PAX hybridisations showed more variability. These obser-
vations indicate that the presence of globin mRNA is an important
factor affecting hybridisation quality control. Of the 75 arrays, 72
passed quality control. Three arrays were excluded for not passing
QC standards, including scale factor and outlying box plots.
Further quality control was carried out on GCRMA normalised
data to check the effects of GC on globin RNA levels. Genespring
12.5 (Agilent) was used to plot the average expression levels of a
number of probe sets in the highest expressing human globin
isoforms (alpha and beta) for each of the five conditions. In the
case of alpha globin probe sets, representative plots (Figure 6A,
B, C) indicate that alpha globin levels are highest in PAX and
TEM samples, while LL are lower, and TEM GC and PAX GC
exhibit the lowest levels of alpha globin mRNA levels. A similar
pattern is also seen in the case of beta globin (Figure 6D).
Analysis in MAS5.0 was carried out to determine the effect of
globin clearance on transcripts present. Analysis of the number of
transcripts present in all arrays for each condition (Figure 7)
indicated that globin clearance unmasks a large percentage of
Gene Expression Profiling of Blood in ALS
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transcripts that would otherwise not be detected. Comparing all
arrays in each condition for transcripts called present (Figure 7A),
indicated that arrays from ‘‘globin positive’’ conditions (PAX and
TEM) exhibited far less present transcripts than ‘‘globin negative’’,
globin depleted samples from PAX GC and TEM GC. The LL
method which enriches RNA from leukocytes revealed present
calls similar to the ‘‘globin negative’’ group of conditions. This
pattern was also similar when comparing present calls in either
controls only or patients only (data not shown). Venn diagrams
comparing number of present calls between LL, PAX and TEM
showed 9632 probe sets in common, while a comparison between
LL PAX GC and TEM GC, exhibited 15576 probe sets in
common (Figure 7B, C). A further comparison between the these
two populations of transcripts indicated 6022 probe sets in the
population of 15576 that were called present in the ‘‘globin
negative’’ group representing genes unmasked by globin depletion
(Figure 7D). DAVID analysis was carried out with the 6022
probe sets. Genes associated with intracellular organelles, most
notably the nucleus and mitochondria were identified, including
many related to transcription (see Table S1).
Gene expression analysis
Using QLUCORE OMICS Explorer, principal component
analysis (PCA) on GCRMA normalised samples that took into
account the expression levels of all probe sets on the arrays showed
that 2 main clusters were visible and broadly corresponding to
globin levels (Figure 8A). A tightly related ‘‘globin negative’’
cluster included the following conditions (LL, TEM GC and PAX
GC), while a more variable ‘‘globin positive’’ cluster (PAX and
TEM) was also present. Taking together this observation with the
potential importance of 6022 probe sets uncovered by globin
depletion to the ontology of ALS, subsequent gene expression
analysis was carried out on the conditions in the ‘‘globin negative’’
group while ‘‘globin positive’’ samples were excluded.
A PUMA analysis of differentially-regulated genes between
patients and controls was carried out, and the three conditions
revealed the following number of statistically significant (p#0.05)
differentially regulated probe sets: LL, 3047; TEM GC, 3619;
PAX GC 4511 (Figure 8B). A Venn diagram comparing these
results showed that 142 probe sets were in common between the
three conditions, while TEM GC and PAX GC shared more
common probe sets than either LL and TEM GC or LL and PAX
GC. Due to the longer preparation time and additional steps
required for PAX GC, PCR validation of gene lists were only
carried out in the case of LL and TEM GC conditions (see
Tables S2 and S3 for identities of differentially regulated probe
sets for LL and TEM GC respectively). A control analysis was also
carried out in order to measure the probability of measuring the
number of differentially regulated genes in any two random groups
of people of a similar size. This would help identify the amount of
noise in our methods. The 15 individuals were randomly sorted
into two groups five times (not based on ALS status) and these
groups were compared against each other. PUMA analysis carried
out for each random group pairing demonstrated the number of
differentially regulated genes between groups was lowest in the
case of LL with an average of 37.74% 610.54 of the original
number of genes. TEM GC exhibited more noise, with an average
of 46.91% 618.49 decrease compared to the number of genes in
the original study (Table S4).
Figure 1. Experimental Design. 5 blood samples were drawn from each of 8 patients and 7 controls were extracted by three methods:
LEUKOLOCK, LL; PAXGENE, PAX(x2); TEMPUS, TEM(x2). Samples were extracted separately and not pooled. Additional aliquots of RNA extracted from
PAX and TEM samples were depleted for globin RNA using GlobinClear. The resulting 75 samples were amplified by IVT and run on Affymetrix U133
Plus 2.0 whole human genome arrays and analysed with MAS5.0, GCRMA or with the R package PUMA.
doi:10.1371/journal.pone.0087508.g001
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Real time PCR validation
To determine the reproducibility of the methods, 6 differentially
regulated genes were chosen from each of the LL and TEM GC
gene lists for real time PCR validation. These genes exhibited a
fold change of at least61.5 (patient versus control), with two genes
from high, medium and low probability (as calculated by PUMA)
Figure 3. RNA quality and quantity, pre and post in vitro transcription. Diagrams showing averages of all samples in the extent of yield from
the 5 experimental conditions (with standard deviation) for (A) RNA extracted, and (C) aRNA produced post IVT, as well as (B) average RIN values of
extracted RNA.
doi:10.1371/journal.pone.0087508.g003
Figure 2. Representative Bioanalyzer electropherograms after initial RNA extractions. High quality RNA (RIN .7.0) can be extracted from
all three methods. PAXGENE however requires a DNase step as traces from initial extractions show genomic DNA contamination at high molecular
weights and as a ‘‘shoulder’’ to the 28S peak (indicated by asterisks). Good quality RNA can be detected after globin depletion with both TEM and
PAXGENE. However, PAXGENE samples showed consistently lower concentration levels, as indicated by the smaller 18S and 28S peaks (FU,
fluorescent units). Traces are representative and from single samples from each extraction method.
doi:10.1371/journal.pone.0087508.g002
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Figure 4. Representative Bioanalyzer electropherograms after IVT and labelling, pre- and post- fragmentation. After IVT, the aRNA
profiles from each method showed distinctly different profiles. Generally, IVT resulted in a wide range of detectable products. However in the cases of
TEM and PAX especially, distinct high intensity peaks were observed in all cases (black arrows). These disappeared in all cases in the globin mRNA
depleted samples. After fragmentation, aRNA profiles were indistinguishable from each other (FU, fluorescent units). Traces are representative and
from single samples from each extraction method.
doi:10.1371/journal.pone.0087508.g004
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values were chosen. PCR calculated fold change values were
calculated from patient and control DCt values (Figure 9).
In the case of LL, 4 out of 6 genes were validated with
significance: CDK1, EGR1, SSPN, and IL23R (all p,0.05 with t-
test), while 2 genes were not validated as being regulated in the
same direction as the arrays: MBLN3 and FOXP1.
In the case of TEMPUS/GC, 4 out 6 genes were validated with
significance: EP400, E2F2, EHBP1 and KAZ (all p,0.05), while
one gene was regulated in a similar way to that seen in the array
without significance: IGHMBP2 (p = 0.11), and 1 gene, PPP1R10,
was not found to be regulated in a similar way observed with the
arrays.
In summary both methods were able to validate two-thirds (4/6)
of the genes chosen thereby indicating that these methods are
similarly reliable. However the reliability of a method in terms of
gene validation by PCR does not necessarily correlate with the
relevance of the method to uncovering genes important in the
disease process, therefore gene ontology studies were carried out
on the lists of differentially expressed genes identified by the two
methods.
Gene Ontology and KEGG pathway analysis
Initially, functional annotation clustering was carried out using
DAVID. In the case of TEMPUS/GC 439 clusters were identified
of which the top 15 are ranked (Table 3). In the case of LL, when
high stringency was used, 383 gene clusters were identified of
which the top 15 are ranked in Table 4.
Figure 5. Initial quality control for the 75 microarrays. Analysis of array data of all 75 samples run was carried out in Affymetrix Expression
Console. PolyA (A) and Hyb (B) controls show that the preparation steps were consistent, and that in general all hybridisations were consistent, but
that hybridisation of PAX samples differed from the rest. The % present call (C) values were generally consistent in LL, TEM GC and PAX GC samples,
but were clearly lower with TEM and PAX gene samples. The scale factor between chips were generally low, except for PAX hybridisations (D) while
the relative log expression (E) of all chips were generally similar with a few exceptions, and a slight general increase in PAX samples (FU, fluorescent
units).
doi:10.1371/journal.pone.0087508.g005
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Table 1. Selected QC metrics for LL, PAX GC, and TEM GC arrays.
SAMPLE SF RawQ BG Avg %P Signal(All) Actin Signal Actin 3-5-ratio
L11.mas5 5.41 1.069 36.00 48.03 800.34 24743.10 1.70
L17.mas5 6.18 0.895 32.19 46.62 834.18 23757.47 1.56
L9.mas5 5.91 0.988 33.04 45.26 844.21 25644.59 1.51
LL10.mas5 5.80 0.933 32.05 47.53 835.55 27377.06 1.89
LL13.mas5 5.12 1.105 37.56 45.75 835.02 25089.33 1.79
LL14.mas5 6.41 0.886 32.41 46.01 862.30 25579.43 2.20
LL15.mas5 5.58 0.979 34.04 46.83 807.15 22601.53 1.81
LL16.mas5 5.10 1.072 36.19 47.97 825.45 25326.25 1.59
LL3.mas5 4.69 1.069 36.63 47.58 838.55 25897.72 2.53
LL4.mas5 5.04 1.123 36.98 45.68 855.88 27424.78 1.98
LL5.mas5 4.55 0.975 33.86 49.79 800.92 21785.49 2.00
LL6.mas5 7.74 0.927 31.35 40.82 852.72 11837.65 275.17
LL7.mas5 4.77 1.017 34.77 47.43 805.97 23906.62 1.98
LL8.mas5 6.29 1.013 36.10 47.17 865.76 26674.71 3.14
AVERAGE LL 5.61 1.004 34.51 46.61 833.14 24117.55 21.49
PGC10.mas5 6.18 0.929 33.08 46.85 837.54 33574.54 1.93
PGC11.mas5 6.47 0.786 29.42 48.07 854.88 20879.55 8.82
PGC12.mas5 5.69 0.981 34.25 47.93 846.99 30065.17 2.15
PGC13.mas5 10.07 0.815 29.56 46.55 853.42 28817.46 3.72
PGC14.mas5 6.85 0.867 30.80 47.52 859.75 39770.83 1.98
PGC15.mas5 9.06 0.794 30.19 46.09 840.79 36071.60 1.91
PGC16.mas5 9.00 0.758 28.10 46.52 839.78 33665.33 2.00
PGC17.mas5 9.11 0.809 30.21 47.53 831.49 36207.19 2.09
PGC3.mas5 7.46 0.853 31.14 49.12 799.54 22522.94 3.76
PGC4.mas5 7.20 0.841 31.68 46.57 834.47 24207.18 2.05
PGC5.mas5 6.67 0.805 30.30 46.76 848.39 27207.11 4.63
PGC6.mas5 7.05 0.810 30.77 48.14 857.44 31168.63 2.60
PGC7.mas5 9.54 0.797 28.21 45.95 824.95 25551.37 3.16
PGC8.mas5 10.50 0.837 30.15 45.54 878.26 25963.42 6.24
PGC9.mas5 8.41 0.824 30.36 47.32 840.14 31464.83 2.16
AV. PAX GC 7.95 0.834 30.55 47.10 843.19 29809.14 3.28
TGC10.mas5 7.25 0.742 28.55 46.77 849.67 26659.93 3.11
TGC11.mas5 7.68 0.850 30.91 44.99 894.94 34257.72 2.38
TGC13.mas5 5.35 0.929 32.32 47.71 830.59 23271.15 1.65
TGC14.mas5 7.54 0.907 31.90 46.60 887.95 17859.96 4.57
TGC15.mas5 9.20 0.877 30.67 46.17 898.22 24888.27 2.78
TGC16.mas5 7.55 0.899 31.09 44.94 863.72 28973.61 1.98
TGC17.mas5 7.32 0.774 30.01 46.33 854.87 28358.92 2.52
TGC3.mas5 6.54 0.914 32.23 48.20 842.43 26744.92 1.67
TGC4.mas5 7.79 0.804 29.63 46.08 871.79 22305.48 11.67
TGC5.mas5 14.24 0.809 31.02 41.56 1046.02 28440.89 84.00
TGC6.mas5 5.84 1.103 36.25 47.36 892.02 30772.99 1.78
TGC7.mas5 6.34 0.876 31.12 47.24 830.87 27208.15 1.98
TGC8.mas5 5.83 0.866 30.90 46.73 824.06 24356.15 1.61
TGC9.mas5 8.18 0.807 29.94 47.05 851.78 23093.71 2.32
AV. TEM GC 7.62 0.868 31.18 46.27 874.21 26227.99 8.86
Scale factor (SF), rawQ, background (BG), percentage present (%P), total signal, actin signal, as well as actin 39 to 59 ratio are all listed for LL, PAX GC and TEM GC arrays
used for this study. Three arrays in total did not pass quality control and were not analysed: one array was extracted by the LL method, one array by TEM GC and one
from TEM.
doi:10.1371/journal.pone.0087508.t001
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Although there are similarities between the 2 lists in terms of
cluster identification, e.g. nucleus/intracellular organelle, apopto-
sis/cell death, nucleotide binding, RNA recognition motifs and
transcription/transcriptional regulation all being found to be
enriched with both methods, there are major differences too. The
extent of enrichment in TEM GC for the top 3 clusters: ribosome,
nucleus and RNA splicing was much greater than the top 3
clusters for LL (nucleus, RNA recognition motif and nucleotide
binding) and of the top 3 clusters in TEM GC, ribosome and RNA
splicing were not present in the top 15 LL clusters. (In LL, splicing
was ranked as 27, with an enrichment of 2.32, while ribosome
biogenesis/RNA processing and metabolic processes was ranked
as 267) Of the top 3 LL clusters, all 3 are found with the top 15
TEMPUS/GC clusters.
KEGG pathway analysis was also carried out in DAVID, in
order to give an indication of the extent of detected changes in
intracellular pathways with each experimental method (See
Tables S5 and S6). KEGG analysis of the LL gene list revealed
dysregulation of 45 pathways including a number of signalling
cascades such as MAPK, Jak-STAT, and phosphatidylinositol and
associated receptor-mediated pathways (Table S5). KEGG
analysis of the TEM GC gene list indicated 33 affected pathways
(Table S6). Specific signalling cascades observed in the LL list
were absent, however a number of common receptor-associated
pathways were affected, e.g. Insulin signalling pathway, Neuro-
trophin signalling, B-cell receptor signalling. Comparing between
the two KEGG pathways analyses, LL and TEMPUS share 17
common dysregulated pathways (accounting for 38% of LL
pathways, and 52% in the case of TEM GC).
Taken together, this analysis suggests that TEM GC and LL
methodologies are similarly consistent when choosing genes to
validate by qPCR, and that whilst they do result in similar
enrichment in affected gene ontologies, the data from TEMPUS/
GC shows more statistical significance.
Table 2. Selected QC metrics for PAX and TEM arrays.
SAMPLE SF RawQ BG Avg %P Signal(All) Actin Signal Actin 3-5-ratio
P13.mas5 23.86 0.832 29.48 33.74 910.39 41134.71 2.37
P16.mas5 20.97 0.805 30.11 33.61 908.23 35056.00 2.30
PG10.mas5 16.53 0.779 29.05 37.72 917.59 46817.15 2.25
PG11.mas5 26.34 0.784 29.39 32.91 975.39 58756.44 3.95
PG12.mas5 28.01 0.800 30.19 30.45 949.32 38274.88 3.03
PG14.mas5 20.69 0.773 29.40 34.20 937.87 49253.10 2.31
PG15.mas5 15.86 0.877 31.80 36.87 873.14 38324.91 2.23
PG17.mas5 13.24 0.792 29.55 39.35 848.18 33711.05 2.80
PG3_1.mas5 41.31 0.706 27.23 29.97 997.94 49350.14 31.60
PG4_1.mas5 51.73 0.744 28.46 26.93 1016.88 31745.37 48.67
PG5.mas5 17.60 0.769 28.84 36.57 959.76 45626.00 2.13
PG6.mas5 21.69 0.840 30.15 31.64 927.78 42699.89 3.18
PG7.mas5 12.57 0.930 32.50 38.57 867.41 33979.42 2.09
PG8.mas5 17.66 0.851 30.08 35.65 906.00 35655.77 2.38
PG9.mas5 16.20 0.839 31.17 37.20 886.68 24967.63 1.73
AV. PAX 22.95 0.808 29.83 34.36 925.51 40356.83 7.53
T10.mas5 6.83 0.896 32.21 43.27 841.55 25843.87 1.67
T11.mas5 9.42 0.883 32.82 41.37 882.21 29647.80 1.42
T12.mas5 14.88 1.009 33.58 35.12 942.61 33275.39 1.37
T13.mas5 8.67 1.037 35.47 40.05 893.06 29685.47 1.38
T15.mas5 13.33 0.873 30.23 37.99 897.58 26182.47 1.60
T16.mas5 10.01 0.987 32.56 39.78 933.23 28284.56 1.25
T17.mas5 9.47 0.864 31.85 41.78 877.22 28296.21 1.23
T3_1.mas5 9.61 0.990 32.90 42.47 893.88 32139.52 1.46
T4.mas5 10.17 0.959 33.49 41.51 886.43 28244.28 1.44
T5.mas5 11.12 0.953 32.65 40.48 872.70 24144.52 1.66
T6.mas5 10.41 1.127 37.35 37.16 884.89 33334.57 1.30
T7.mas5 8.29 1.138 38.70 40.82 909.65 38670.56 1.40
T8.mas5 8.37 1.144 37.47 37.94 914.99 40451.85 1.26
T9.mas5 12.92 0.887 31.10 38.73 893.45 28633.24 1.56
AV. TEM 10.25 0.982 33.74 39.89 894.53 30488.16 1.43
Scale factor (SF), rawQ, background (BG), percentage present (%P), total signal, actin signal, as well as actin 39 to 59 ratio are all listed for PAX and TEM arrays used in this
study. Three arrays in total did not pass quality control and were not analysed: one array was extracted by the LL method, one array by TEM GC and one from TEM.
doi:10.1371/journal.pone.0087508.t002
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Discussion
This study compares three RNA extraction methods from blood
and their suitability for GEP in a neurological disease such as ALS.
All three methods allow blood drawn to be stored in stabilizing
agents and therefore provide alternatives to traditional PMBC
isolation which requires the immediate processing of blood
samples [14]. Two column based methods (PAX, TEM) resulting
in total blood RNA extraction and one method which enriches for
the leukocyte population were used (LL). Previous studies indicate
that long term storage of blood in RNA stabilizing solutions does
not adversely affect the transcript profile in extracted RNA [8,15–
17]. However, there have been reported differences between PAX
and TEM methods [11,17,18]. Here we are the first to compare
whole blood extraction methods with a leukocyte enrichment
method in human blood. In addition, globin depletion was carried
out on PAX and TEM blood samples in order to compensate for
the masking effects of high levels of alpha and beta globin
transcripts using the commercially available GC method [7,19]. In
total 5 conditions were therefore assessed and compared, LL,
TEM, TEM/GC, PAX and PAX/GC.
Blood extraction and RNA isolation
Blood was drawn directly into TEM and PAX tubes containing
RNA stabilizing solutions, the two methods required relatively
small amounts of blood (3 ml and 2.5 ml respectively) and stored
at 220uC after the required mixing (PAX also requires 2 hours
incubation at room temperature before freezing). In the case of
LL, a larger quantity of blood, 8–9 ml, was first collected in a
standard vacutainer blood collection tube before being filtered into
another collection tube. The LL filter required flushing with PBS
and saturating with RNAlater before being stored at 220uC
directly. For RNA extraction, using the 2 column-based methods,
TEM required less time to carry out compared to PAX, also TEM
Figure 6. Quality control: globin levels in arrays. Data were GCRMA normalised and levels of 3 representative alpha globin probe sets (A, B and
C) and one beta probe set (D) were averaged for each condition. Expression level box plots indicate that in both the cases of alpha and beta globin,
TEM and PAX exhibit highest levels of globin mRNA while TEM GC and PAX GC were the lowest, LL levels were generally lower than PAX and TEM, but
higher than PAX GC and TEM GC.
doi:10.1371/journal.pone.0087508.g006
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extraction resulted in high yield, high quality pure RNA without
the requirement of DNAse step, which was required for PAX,
(though this may be accounted for by the slightly smaller amount
of blood drawn). LL extraction resulted in intermediate yield but
also required less time to carry out than PAX. These observations
are in broad agreement with previous studies [17]. Isolation of
RNA with the LL method also took less time and experimental
manipulation than PAX, and also resulted in high yield, high
quality RNA without the need for a DNase step.
Globin depletion
Globin depletion was carried on PAX and TEM extracted RNA
samples using GlobinClear. Levels of the most abundant globin
alpha and beta globin isoforms in adult human blood showed
reduction in these samples, compared to non-globin cleared
samples and averaging lower than levels in LL, but with greater
variability. LL samples did exhibit residual levels of globin mRNA,
which were also lower than non-globin cleared samples. Previous
studies suggested that GC depletion results in lower RNA quality
and RIN values [9]. We did not observe any reduction in RNA
quality, although the RNA yield was reduced, which was more
marked in the PAX samples. GC utilises oligonucleotides that
target the 2 most abundant human globin species (alpha and beta,
[20]), yet similar reductions in lower expressing isoforms (i.e. delta,
epsilon and zeta) were also observed in PAX and TEM GC RNA
extractions (data not shown). Globin depletion added an additional
step to the extraction protocol and the additional time and cost of
the procedure must be taken into account when deciding a suitable
method for RNA extraction from blood.
Figure 7. Number of probe sets called present increases after globin depletion. MAS5.0 normalised data indicated that the presence of
globin affects the number of probes sets called present. Comparison of all probe sets called present in every array for each condition reveals higher
numbers in the case of LL, TEM GC and PAX GC (‘‘globin negative’’) as compared to TEM and PAX (‘‘globin positive’’; A). Comparison between probe
sets called present in LL, TEM and PAX reveals 9632 probe sets in common (B), and 15576 probe sets were found to be in common between LL, TEM
GC and PAX GC (C). By comparing these 2 populations 6022 probe sets were found to be unmasked by globin depletion (D).
doi:10.1371/journal.pone.0087508.g007
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Figure 8. Gene expression analysis. PCA plotted using QLUCORE OMICS Explorer on GCRMA normalised data: each dot represents an array and
takes into account the expression levels of every probe set and shows 2 main clusters (A). One tightly clustering ‘globin negative’ cluster includes the
following conditions: LL, TEM GC and PAX GC, while a second more variable cluster ‘‘globin positive’’ includes arrays hybridised with PAX and TEM
extracted RNA. Focusing on the globin negative group PUMA analysis identified differentially regulated probe sets (ALS patients vs controls) for the
following (B; LL, 3047; TEM GC, 3619; PAX GC, 4511). A Venn diagram comparing these lists shows that TEM and PAX share more genes in common,
than either with LL, and 142 genes in common between all 3 methods).
doi:10.1371/journal.pone.0087508.g008
Figure 9. Real-time validation PCR for genes in LL and TEM GC gene lists. DCTs plotted for 6 genes chosen for validation using the LL
method of RNA extraction from blood (A). Four out of 6 genes (CDK1, EGR1, SSPN and IL23) could be validated from the Affymetrix microarray studies
(C). DCTs plotted for 6 genes chosen for validation using the TEMPUS/GC method of RNA extraction from blood (B). Four out of 6 genes (EP400, E2F2,
EHBP1 and KAZ) could be validated from the Affymetrix microarray studies (D). Blue bars represent levels of gene expression in ALS patients (n = 6)
and red bars the levels in normal control individuals (n = 6).
doi:10.1371/journal.pone.0087508.g009
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IVT and fragmentation
All methods/conditions yielded sufficient quality and quantity
of RNA to proceed with a reverse transcription reaction. After
second strand synthesis, amplification and production of aRNA by
in vitro transcription was carried out. IVT yield was greatest in the
following order: TEM . LL . PAX . TEM GC . PAX GC.
Additionally, while PAX yielded on average more RNA after
extraction than LL, the latter method resulted in higher levels of
aRNA even though the same amount of input cDNA was used in
the IVT reaction. Possible reasons for this may be explained by
comparing pre-fragmentation profiles of aRNA observed with the
different conditions. Intense discrete peaks at low mass nucleotide
ranges could be observed in all TEM and PAX aRNA profiles
after Bioanalyzer analysis. All TEM profiles exhibited similar
peaks, and all PAX profiles exhibited similar peaks. These
probably represent aRNA populations associated with globin
since following globin depletion these peaks disappeared in all
cases and a wide range of RNA populations were observed in both
TEM and PAX. A similar broad range of aRNA populations were
visible in pre-fragmented LL samples. After fragmentation, profiles
were indistinguishable between methods. These observations
highlight the importance of globin depletion/reduction in RNA
extracted from blood samples, as aRNA populations from globin
skew the relative proportions of other aRNA populations within
samples.
Affymetrix array quality control
Quality control metrics were consistent within each sampling
method. However, when comparing between methods the
saturating presence of globin significantly affected the percentage
of present calls using MAS5 analysis. PAX and TEM present calls
were distinctly lower than LL, PAX GC and TEM GC. Thus,
already we can distinguish two separate groups of arrays, a ‘‘globin
positive’’ group with low % present calls/large scale factor, and a
Table 3. Functional annotation clustering carried out in DAVID for differentially regulated genes from a cohort of ALS patients and
controls, using RNA extracted from blood with LL and TEM GC undergoing PUMA GEP analysis.
LEUKOLOCK Annotation
Cluster Enrichment Score Terms
1 10.86 intracellular organelle lumen incuding nucleus
2 9.29 RNA recognition motif/RNP-1
3 7.41 nucleotide binding
4 7.06 phosphate/phosphorus metabolic processes/phosphorylation
5 6.66 transcription/transcription regulation
6 5.78 zinc finger/zinc/zinc ion binding
7 4.62 serine/threonine protein kinase/protein kinase activity
8 4.23 protein catabolic processes
9 4.21 apoptosis/cell death
10 3.99 helicase activity
11 3.77 protein transport/localisation
12 3.62 Lissencephaly type-1-like homology motif
13 3.21 zinc finger, PHD type
14 3.08 Bromodomains
15 2.83 pleckstrin homology
TEMPUS GC Annotation
Cluster Enrichment Score Terms
1 and 2 34.43/29.37 Ribosome
3 22.94 intracellular organelle lumen incuding nucleus
4 12.06 RNA splicing
5 6.53 regulation of apoptosis
6 6.51 ribosome biogenesis, RNA processing and metabolic processes
7 6.31 RNA recognition motif/binding
8 and 9 5.58/4.80 apoptosis and cell death
10 4.72 protein transport/localization
11 4.25 mitochondrial membrane
12 4.23 nucleotide binding
13 3.7 lysososome/lytic vacuole
14 3.44 transcription/transcription regulation
15 3.41 Like-Sm ribonucleoprotein (snRNP’s)
In the case of LL, out of 383 clusters, the top 15 are ranked in order of enrichment score (upper section). In the case of TEM GC, out of 439 clusters, the top 15 are ranked
in order of enrichment score (lower section). Common clusters between LL and TEM GC are labelled in italic and underlined.
doi:10.1371/journal.pone.0087508.t003
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‘‘globin negative’’ group with higher % present calls/low scale
factor. The identity of these 2 groups is highlighted in the PCA
plot in Figure 8. The arrays within the ‘‘globin negative’’ group
are much more tightly related than the arrays in the ‘‘globin
positive’’ group which exhibit much more variability. These
observations were underpinned by an approximate 60% increase
in transcript present calls in the ‘‘globin negative’’ group compared
to the ‘‘globin positive’’ group (15576 vs 9632 respectively). GO
analysis of the approximately 6000 additional transcripts called
present in the globin negative group revealed many genes
associated with the nucleus, gene transcription and mitochondria.
A number of these genes could be potentially be important in the
aetiology/progression of ALS, given the current focus on defects in
RNA transcription and processing as well as oxidative stress [2].
Levels of alpha and beta globin isoforms mirrored the expected
globin status throughout all conditions, and although LL globin
levels were higher than TEM GC and PAX GC, they exhibited
less variability between samples. When comparing the number of
present calls of LL with other conditions, more transcripts were
found to be present and in common with TEM GC/PAX GC as
compared to TEM/PAX, indicating that residual globin levels in
LL do not obscure the visibility of lower expressed transcripts on
arrays, in comparison with the GC depleted samples.
Real-time PCR validation of differentially regulated genes
and gene ontology differences
Using the PUMA bioconductor package [21], lists of differen-
tially regulated genes in ALS as compared to controls were
produced from LL, TEM GC and PAX GC samples. Comparison
of these gene lists indicated that PAX GC and TEM GC shared a
larger number of common differentially regulated genes, com-
pared with LL. This difference can be explained when considering
that the starting material in PAX and TEM cases was whole
blood, containing additional cell populations, while LL enriches
for leukocytes. A control analysis was also carried out with LL and
TEM GC samples, where the 15 subjects were randomly assigned
into 2 groups irrespective of ALS status and gene expression
analysis with PUMA was carried out in order to ascertain the
probability of finding differentially regulated genes in any two
random groups of subjects of a similar size. After 5 iterations, the
average number of differentially regulated genes (expressed as a
percentage of the original study) was lower in LL than TEM GC,
suggesting less noise in the LL data. An average of almost 40% of
the original number of genes (approx 1200) is likely to be seen as
differentially expressed in any random study. Although a number
of these may be bona-fide targets, this highlights the difficulty
involved in identification of actual disease markers using the
techniques employed in this study.
Due to the technical limitations of the PAX technique (low yield
after additional methodological manipulation), this method was
disregarded for PCR validation which was carried out on LL and
TEM GC samples, as they represent better methods for GEP
profiling. Six genes were chosen with a minimum of 1.5 fold
difference between disease and controls for each method and real-
time PCR resulted in the validation of 4 out of 6 genes for each
condition, indicating that both methods present similar consistency
and reliability. These similarities in consistency between the 2
methods may not represent similarities in differential regulation of
gene pathways, and therefore GO functional annotation clustering
analysis was carried out on the respective gene lists to ascertain
putative differences/similarities. Considering the a) relatively few
differentially regulated genes in common between the 2 methods,
and b) the difference in starting material (whole blood versus
leukocyte enriched), GO analysis revealed a striking similarity in
the number of common cluster terms, and this was supported by
similar observations when carrying out KEGG pathway analysis.
It is noteworthy that the top cluster terms, ribosome-associated
genes, in TEM GC were not present in LL, and this raises the
question as to whether these are associated with pathological
changes and/or mirror underlying differences in initial cell
populations used as starting material for each extraction method.
As there are only small differences between globin levels (depleted
and undepleted isoforms) in TEM GC samples when comparing
patients and controls (data not shown) we can discount any
potential sampling/extraction bias leading to the observed
differences in ribosome-associated gene expression. Taking into
account the relatively small number of ALS patients and controls
in this study, drawing conclusions regarding pathway analysis
should be cautious, however examples of pathways involved in
ALS include: defects in RNA processing [2], and thus changes in
expression of ribosome-associated genes during disease may arise
from the aggregation of proteins such as TDP-43 and FUS, and
down-stream effects e.g. on stress granule formation arising from
Table 4. PCR primer sequences designed for genes validated
in this study.
LEUKOLOCK
Gene Sequence Product Size
FOXP1 S ctctgtcatcacaaccaccag 138
AS ggtggtctaacttctgcgttc
IL23R S ggcaagaagtacttggtttgg 128
AS atagtctcagccctggaaatg
CDK1 S aggtcaagtggtagccatgaa 108
AS tttggatgacgaagttccttt
EGR1 S gagaaggtgctggtggagac 142
AS cactgaccaagctgaagagg
MBNL3 S tccatcaattccagctaatcc 112
AS tccaggaatcagaacaggtg
SSPN S ttacctgtgagaccacactcg 108
AS cagtgacgctggtacagtcc
TEMPUS GC
Gene Sequence Product Size
PPP1R10 S acaagccactcaacacaacac 107
AS ggctgaattaagagcatccag
KAZ S ctagccagagccaaagaagc 150
AS atagttgcggatgaagtctcg
EHBP1 S attctgcaacaggcagctaag 109
AS tgacatcttcactccagatcg
E2F2 S gccaagaacaacatccagtg 102
AS gttcatcagctccttcagctc
IGHMBP2 S gctgacattcttcaacacctg 132
AS atgatctcaaccacagtcgtg
EP400 S ctggtcattgatgagatgcag 131
AS cagagctccaggaaggtattg
Samples of cDNA were diluted 1:10, and 2.5 ul were used per PCR reaction for
all genes except EHBP1, where 4 ml was used with 5x Brilliant III Ultra Fast SYBR
Green QPCR Master Mix (Agilent). In all cases primer concentrations were
optimised to 300 mM (S, sense strand; AS, antisense strand)
doi:10.1371/journal.pone.0087508.t004
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dissociating ribosomes [22]. In addition, the most striking
differences in LL-KEGG pathway analysis were the enrichment
for specific intracellular signalling pathways, such as MAPK, and
PI3K, cascades commonly involved in signal transduction from
the cell membrane and involved in cell survival in ALS [23,24] as
well as the JAK/STAT pathway, a regulator of neuronal apoptosis
[25].
Conclusions
GEP with blood is a feasible approach for biomarker discovery
in neurological disease. Overlap in transcript expression and
splicing between blood and neural tissues has been demonstrated
[6]. The present study primarily highlights the importance of
reducing the high levels of globin present when using blood for
GEP profiling in neurological disease [7]. After reduction in globin
levels, the expression of ,30% of additional transcripts are
unmasked, many with functions of potential importance in the
pathophysiology of ALS. Although reduction in globin was
achieved through different methods, remarkably similar results
were obtained when comparing dysregulated pathways in ALS.
The preferred TEM GC and LL methods produced the highest
yield, most consistent array performance, and similar reliability
when validating gene targets with real-time PCR. PAX was more a
labour-intensive method, also produced good quality RNA but
with lower yield and, after subsequent globin depletion, RNA
quality was reduced. In future biomarker studies when making a
decision regarding which method to use, the extra cost and the
time required for the globin depletion step in the case of TEM
must be considered against the larger volume of blood required for
LL. Although we have not analysed whether any of our validated
genes correspond to bone-fide hits for biomarkers, future studies
should concentrate on the identification and validation of potential
targets that may arise as bona-fide biomarkers for ALS. Single
targets or clusters of targets can be validated by PCR in either
human samples or those from animal models in a blinded fashion
to see whether they are predictive of ALS or in the case of serial
sampling, of disease progression.
Methods
Blood collection
Ethical approval for the study was granted from South Sheffield
Ethics Committee and written informed consent from each subject
was obtained before commencing. Blood was collected after an
overnight fast from patients (n = 8) or age- matched controls (n = 7,
see Table 5) either directly into PAX/TEM tubes (approx. 3 ml)
or into K2EDTA spray-coated collection (BD Vacutainer) tubes
(approx. 8–9 ml), for immediate passage through a LL filter. RNA
was stabilized in PAX and TEM tubes by slow inversion (PAX) or
vigorous shaking (TEM) for 30 and 15 seconds respectively. LL
filters were washed with PBS and saturated with RNAlater as
described in the manufacturer’s instructions. Samples were stored
at 220uC until processed further.
RNA extraction and Globin depletion
RNA was extracted by PAX (Qiagen), TEM (Applied Biosys-
tems) and LL (Ambion) methods as described in the respective
maufacturer’s instructions, in each case omitting any DNase step.
All samples were extracted separately and not pooled. The quality
and yield of extracted RNA was analysed by examining
electropherogram traces generated by the 2100 Bioanalyzer
(Agilent) running the samples on a total eukaryote RNA nano
chip, and by UV spectrography using Nanodrop 1000 (Thermo
Scientific). Samples were stored at280uC until required for globin
depletion (TEM) or amplification (LL). Before globin depletion
was carried out on TEM and PAX samples, PAX samples
underwent DNase (NEB) treatment (2 mg of RNA, 2U DNase I)
for 10 mins at 37uC followed by addition of EDTA to a final
concentration of 5 mM and subsequent heat inactivation at 75uC
Table 5. Characteristics of subjects taking part in the study.
PATIENT ID SAMPLE DATE AGE GENDER DIAGNOSIS/RILUZOLE
3 05/04/2012 57 M ALS/R
4 12/04/2012 53 F ALS/R
13 19/04/2012 72 M ALS/-
7 26/04/2012 64 M ALS/-
8 26/04/2012 60 M ALS/-
16 11/05/2012 62 F ALS/R
9 11/05/2012 63 F ALS/R
17 12/06/2012 71 M ALS/-
CONTROL ID SAMPLE DATE AGE GENDER MATCHED TO
11 05/04/2012 55 F P TO 3
5 12/04/2012 56 M P TO 4
6 19/04/2012 47 F NBLD REL 13
12 27/04/2012 57 F P TO 8
10 15/04/2012 63 M
14 17/05/2012 62 F P TO 7
15 12/06/2012 69 F P TO 17
Table indicating patient and control IDs used for this study, as well as blood sample extraction date, age, gender, diagnosis and whether patient was treated with
Riluzole. Controls that were matched to patients are also indicated (M=male, F = female, R = treated with Riluzole, P = partner, NBLD REL = non-blood relative). Samples
from underlined patients and controls were used in PCR validation.
doi:10.1371/journal.pone.0087508.t005
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for 10 mins. Samples were run on the 2100 Bioanalyzer to
measure quality, and subsequent globin depletion (GlobinClear,
Ambion) was carried out with 1 mg of RNA as described in the
manufacturer’s instructions. Where the RNA concentration was
,67 ng/ml, samples had to be concentrated using 50 mg/ml
Glycoblue (Ambion), in 0.5 M ammonium acetate, 50% isopro-
panol.
RNA Amplification and Affymetrix microarray analysis
Linear amplification was employed using the Affymetrix
GeneChip 39 IVT Express Kit according to the manufacturer’s
instructions. 200 ng of total RNA was reversed transcribed to
synthesize first-strand cDNA with oligo(dT) primers containing a
T7 flanking sequence. After second strand synthesis, labelled
aRNA was synthesized in an in vitro transcription reaction. In order
to minimise batch effects, 10 samples were randomly chosen for
each round of IVT. A number of samples had to be concentrated
using 50 mg/ml Glycoblue (Ambion), in 0.5 M ammonium
acetate, 50% isopropanol before fragmentation. 15 mg of aRNA
was fragmented as described in the manufacturer’s instructions
and hybridized overnight onto U133 Plus 2.0 human genome
arrays as previously described [24]. 12 arrays were hybridised per
run and samples to be run were chosen in a similar random
manner to the amplifications in order to minimise batch effects.
After washing the chips in the Affymetrix Fluidics System 450,
they were scanned in the GeneChip 30007G Scanner.
Quality control was initially carried out on Affymetrix
expression console, on MAS5.0 normalised data. The data were
also normalised by GCRMA for further quality control, gender
differences using the program QLUCORE OMICS Explorer and
analysis of globin isoform levels in GENESPRING (Agilent). CEL
file data were analysed by the R package PUMA for compiling a
list of differentially regulated genes. We utilised PPLR (probability
of positive log-ratio), a tool within the PUMA suite that measures
the uncertainty in estimation of gene expression, i.e. the technical
variability, in order to provide a robust estimate of differential
expression and listed significantly differentially regulated genes
with a pLikeValue ,0.05 (Liu et al., 2006). Gene Ontology and
KEGG pathway analysis was carried out using the bioinformatics
tool DAVID [26].
Real-time PCR
200 ng of total RNA from 6 of the patients and 6 of the controls
(Table 5) was reverse transcribed using the High Capacity RNA-
to-cDNA Kit (Applied Biosystems) in reaction volume of 20 ml.
This represented our best quality samples. As calculated from
efficiency plots for each gene, samples of cDNA were diluted 1:10,
and 2.5 ml (2.5 ng) were used per PCR reaction for all genes
except EHBP1, where 4 ml (4 ng) was used with 5x Brilliant III
Ultra fast SYBR Green QPCR Master Mix (Agilent). In all cases
primer concentrations were optimised to 300 mM and reactions
carried out in triplicate. Real time PCR was carried out as
previously described using the MX3000P cycler and MxPro
software for analysis of Ct values. DCt values for each sample were
calculated by subtracting Ct values from genes of interest from
corresponding Ct values of the housekeeping gene GAPDH, which
exhibited consistent expression across all samples. Subsequent
DDCt (DCtpat-DCtcont) were calculated in order to assess fold
changes using the following formula: fold change = 22(DDCt).
Unpaired two-tailed t-tests were used to determine whether
differences in gene expression levels between patients and controls
were statistically significant.
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